|Bid||3.26 x 1100|
|Ask||4.33 x 4000|
|Day's Range||3.31 - 3.39|
|52 Week Range||2.95 - 5.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.58|
NEW YORK, Aug. 29, 2018-- Kadmon Holdings, Inc. today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Rodman & Renshaw 20 th Annual Global Investment Conference ...
NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of C&J ...
Exact Sciences (NASDAQ:EXAS) shares have bolted above both their 50-day and 200-day moving averages, rising nearly 30% in mid-day trading on Wednesday to return to the upper end of a three-month trading range. The company will next report results on Oct. 31, after the bell. When the company last reported on Aug. 1, a loss of 30-cents-per-share beat estimates by 3 cents on a 79% rise in revenues on a year-over-year basis.
Kadmon Holdings, Inc. today provided a business update and reported financial and operational results for the second quarter of 2018.
Kadmon Holdings, Inc. today announced updated efficacy and safety results from an ongoing Phase 2 clinical trial evaluating KD025 in patients with steroid-dependent or refractory chronic graft-versus-host disease .
Kadmon Holdings, Inc. (KDMN) today announced the closing of its previously announced offerings of common stock for gross proceeds of approximately $113.2 million, which includes the full exercise of the underwriters’ option to purchase additional shares. Proceeds from the offerings will be used for preclinical and clinical development of Kadmon’s lead product candidates, discovery, research and preclinical studies of its other product candidates and for other general corporate purposes. “This financing is a testament to the significant potential of KD025 in cGVHD and provides the resources that we believe will allow us to pursue regulatory approval in this indication,” said Harlan W. Waksal, M.D., President and CEO at Kadmon.
Kadmon Holdings (KDMN) is an integrated biopharmaceutical company. On June 11, Kadmon Holdings announced the pricing of its common stock offerings. Following the news, the stock price increased ~9.8% and closed at $3.68 on June 12.
Kadmon Holdings, Inc. (KDMN) today announced the pricing of an offering of an aggregate of 30,303,030 shares of its common stock at an offering price of $3.30 per share in an underwritten offering (the “Underwritten Offering”) and a registered direct offering to certain institutional investors (the “Direct Offering” and, together with the Underwritten Offering, the “Offerings”). The gross proceeds to Kadmon from the Offerings, before deducting underwriting discounts and commissions and other expenses of the Offerings, are expected to be approximately $100.0 million. Kadmon has granted the underwriters in the Underwritten Offering a 30-day option to purchase up to an additional 4,000,000 shares of Kadmon’s common stock on the same terms and conditions.
Kadmon Holdings, Inc. (KDMN) today announced its intention to offer and sell shares of its common stock in a public offering pursuant to an existing shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Jefferies LLC is acting as the sole book-running manager for the offering.
Kadmon Holdings, Inc. (KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present an overview of the Company and its clinical programs at the Jefferies 2018 Global Healthcare Conference in New York on Tuesday, June 5, 2018 at 10:00 a.m. ET. Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company developing innovative products for significant unmet medical needs. This press release contains forward-looking statements.
Kadmon Holdings, Inc. today announced that additional data from its ongoing Phase 2 clinical trial of KD025 in chronic graft-versus-host disease will be highlighted in an oral presentation at the 23rd Congress of the European Hematology Association , to be held June 14-17, 2018 in Stockholm, Sweden.
Kadmon Holdings, Inc. today provided a business update and reported financial and operational results for the first quarter of 2018.
Kadmon Holdings, Inc. today announced that it has received final minutes from a March 2018 Type C meeting with the U.S. Food and Drug Administration regarding the development pathway for KD025, the Company’s Rho-associated coiled-coil kinase 2 inhibitor, for the treatment of chronic graft-versus-host disease .
Kadmon Holdings, Inc. today provided an update on upcoming milestones and recent achievements, and reported financial and operational results for the fourth quarter and full year ended December 31, 2017.
Stock Monitor: Vanda Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 26, 2018 / Active-Investors.com has just released a free research report on Kadmon Holdings, Inc. (NYSE: KDMN ). If ...
Kadmon Holdings, Inc. today announced updated positive results from an ongoing Phase 2 clinical trial evaluating KD025, its Rho-associated coiled-coil kinase 2 inhibitor, in patients with chronic graft-versus-host disease .
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a big mover in the biotechnology space at the start of this week, with the action rooted in an FDA announcement hitting press during the session on Monday. At the start of trade, the company reported that the agency in the US has given a regulatory green light to a […] The post Vertex Pharmaceuticals, Kadmon Holdings Are Early Week Biotech Movers appeared first on Market Exclusive.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Kadmon Holdings Inc (NYSE: KDMN ) stock gained nearly ...
Kadmon Holdings, Inc. today announced that it will hold a webcast and conference call tomorrow, February 13, 2018, at 8:30 a.m. ET. The purpose of this conference call is to discuss topline results from an ongoing Phase 2 clinical trial evaluating KD025, its Rho-associated coiled-coil kinase 2 inhibitor, in patients with idiopathic pulmonary fibrosis who were previously treated with or offered pirfenidone ...